-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neonatal diabetes studies have shown that sulfonylureas can lower blood sugar without causing hypoglycemia, partly because it enhances the effect of incretin.
Diabetic hypoglycemia
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
Researchers performed a paired oral glucose tolerance test and isobaric infusion on 16 patients with type 2 diabetes (HbA1c<64mmol/mol, 8.
Metformin
A single dose of 20 mg gliclazide reduced the average blood glucose concentration during OGTT from 12.
It can be seen that low-dose gliclazide can lower blood sugar and at the same time enhance the effect of classic incretin .
Low-dose gliclazide can lower blood sugar and at the same time enhance the effect of classic incretin
Original source:
Original source:Ruth LM Cordiner.
org/10.
1210/clinem/dgab151" target="_blank" rel="noopener">The impact of low dose gliclazide on the incretin effect and indices of beta cell function in this message